Antithrombotic treatment before and after peripheral artery percutaneous angioplasty

Blood Transfusion

Volumn 7, Issue 1, 2009, Pages 18-23

  Visonà, Adriana ^a,b   Tonello, Diego ^a   Zalunardo, Beniamino ^a   Irsara, Sandro ^a   Liessi, Guido ^a   Marigo, Lucia ^a   Zotta, Laura ^a  

^a San Giacomo Hospital   (Italy)

^b Ospedale 18   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; CLOPIDOGREL; DALTEPARIN; DIPYRIDAMOLE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; TICLOPIDINE; VASOACTIVE AGENT; WARFARIN; FIBRINOLYTIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; PYRIDINE DERIVATIVE; THIENOPYRIDINE DERIVATIVE;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTERY DISEASE; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BLEEDING; BLOOD CLOTTING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAFT PATENCY; HUMAN; IN-STENT RESTENOSIS; INTERMITTENT CLAUDICATION; LIMB ISCHEMIA; LOADING DRUG DOSE; OPTIMAL DRUG DOSE; PEPTIC ULCER; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVASCULARIZATION; REVIEW; RISK REDUCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT DURATION; TREATMENT OUTCOME; VASCULAR DISEASE; VASCULAR PATENCY; DRUG COMBINATION; FIBRINOLYTIC THERAPY; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ASPIRIN; CORONARY RESTENOSIS; DIPYRIDAMOLE; DRUG COMBINATIONS; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOLYTIC THERAPY;

EID: 65449133987     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2008.0008-08b     Document Type: Review

References (43)

1. Diehm C, Schuster A, Allenberg JR, et al. High prevalence of peripheral arterial disease and comorbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 2004; 172: 95-105. (Pubitemid 38058606)
2. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA 2006; 295: 547-553 (Pubitemid 43200349)
3. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113: e463-654.
4. Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction. Description of a new technique and a preliminary report of its application. 1964. Radiology 1989; 172: 904-920 (Pubitemid 19208218)
5. Grüntzig A, Hopff H. Percutaneous recanalization after chronic arterial occlusion with a new dilator-catheter (modification of the Dotter technique). Deutsche Medizinische Wochenschrift 1974; 99: 2502-2511
6. Mahler F, Baumgartner I, Do DD. Stenting of the peripheral renal and supraaortic arteries and the aorta. Schweizerische Medizinische Wochenschrift 1999; 129: 399-409. (Pubitemid 29135399)
7. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Eng J Med 2006; 354: 1879-1888 (Pubitemid 43872689)
8. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Eng J Med 2008; 358: 689-699
9. Fuster V, Falk E, Fallon JT, et al. The three processes leading to post PTCA restenosis: dependence on the lesion substrate. Thrombosis and Haemostasis 1995; 74: 552-559
10. Wentzel JJ, Gijsen FJ, Stergiopulos N, et al. Shear stress, vascular remodeling and neointimal formation. Journal of Biomechanics 2003; 36: 681-688 (Pubitemid 36407620)
11. Schwartz RS. Pathophysiology of restenosis: interaction of thrombosis, hyperplasia, and/or remodeling. American Journal of Cardiology 1998; 81: 14E-17E. (Pubitemid 28182623)
12. Tsakiris DA, Tschöpl M, Jäger K, et al. Circulating cell adhesion molecules and endothelial markers before and after transluminal angioplasty in peripheral arterial occlusive disease. Atherosclerosis 1999; 142:193-200. (Pubitemid 28551825)
13. Tschöpl M, Tsakiris DA, Marbet GA, et al. Role of hemostatic risk factors for restenosis in peripheral arterial occlusive disease after transluminal angioplasty. Arterioscler Thromb Vasc Biol 1997; 17: 3208-3214 (Pubitemid 28016079)
14. Jorgensen B, Meisner S, Holstein P, Tonnesen KH. Early rethrombosis in femoropopliteal occlusions treated with percutaneous transluminal angioplasty. European Journal of Vascular Surgery 1990; 4: 149-152 (Pubitemid 20172199)
15. Haudenschild CC. Pathophysiology of reocclusion and restenosis. Fibrinolysis 1995; 9 (Suppl 1): 44-47
16. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33 (Suppl 1): S1-75. (Pubitemid 46068992)
17. Schillinger M, Exner M, Mlekusch W, et al. Vascular inflammation and percutaneous transluminal angioplasty of the femoropopliteal artery: association with restenosis. Radiology 2002; 225: 21-26
18. Schillinger M, Mlekusch W, Haumer M, et al. Angioplasty and elective stenting of de novo versus recurrent femoropopliteal lesions: 1-year follow-up. Journal of Endovascular Therapy 2003; 10: 288-297 (Pubitemid 36988602)
19. Gallino A, Mahler F, Probst P, Nachbur B. Percutaneous transluminal angioplasty of the arteries of the lower limbs: a 5 year follow-up. Circulation 1984; 70: 619-623 (Pubitemid 14020659)
20. Decrinis M, Pilger E, Stark G, et al. A simplified procedure for intra-arterial thrombolysis with tissue-type plasminogen activator in peripheral arterial occlusive disease: primary and long-term results. Eur Heart J 1993; 14: 297-305. (Pubitemid 23103411)
21. Duda SH, Pusich B, Richter G, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation 2002; 106: 1505-1509
22. Minar E, Pokrajac B, Maca T, et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation 2000; 102: 2694-2699
23. Bonvini R, Baumgartner I, Dai Do D, et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. J Am Coll Cardiol 2003; 41: 409-412 (Pubitemid 36164494)
24. Dörffler-Melly J, Koopman MMW, Prins MH, Büller HR. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev. 2005; (1): CD002071.
25. Weichert W, Meents H, Abt K, et al. Acetylsalicylic acid reocclusion prophylaxis after angioplasty (ARPA study). A randomized double-blind trial of two different dosages of ASA in patients with peripheral occlusive arterial disease. Vasa 1994; 23: 57-65.
26. Minar E, Ahmadi A, Koppensteiner R, et al. Comparison of effects of high-dose and low-dose aspirin on restenosis after femoropopliteal percutaneous transluminal angioplasty. Circulation 1995; 91: 2167-2173
27. Ranke C, Creutzig A, Luska G, et al. Controlled trial of high-versus low-dose aspirin treatment after percutaneous transluminal angioplasty in patients with peripheral vascular disease. Clinical Investigator 1994; 72: 673-680 (Pubitemid 24304084)
28. Schweizer J, Müller A, Forkmann L, et al. Potential use of a low-molecular-weight heparin to prevent restenosis in patients with extensive wall damage following peripheral angioplasty. Angiology 2001; 52: 659-669 (Pubitemid 32963569)
29. Faxon DP, Spiro TE, Minor S, et al. Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial. Circulation 1994; 90: 908-914
30. Koppensteiner R, Spring S, Amann-Vesti BR, et al. Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: A randomized controlled trial. J Vasc Surg 2006; 44: 1247-1253 (Pubitemid 44834599)
31. Dörffler-Melly J, Mahler F, Do D, et al. Adjunctive abciximab improves patency and functional outcome in endovascular treatment of femoropopliteal occlusions: initial experience. Radiology 2005; 273: 1103-1107 (Pubitemid 41636408)
32. Cassar K, Ford I, Greaves M, et al. Randomized clinical trial of the antiplatelet effects of aspirin-clopidogrel combination versus aspirin alone after lower limb angioplasty. Br J Surg 2005; 92: 159-165 (Pubitemid 40269328)
33. Cassar K, Bachoo P, Ford I, et al. Clopidogrel has no effect on D-dimer and thrombin-antithrombin III levels in patients with peripheral percutaneous transluminal angioplasty. J Vasc Surg 2005; 42: 252-258
34. th Edition). Chest 2008; 133 (6 Suppl): 815s-43s.
35. Catalano M, Born G, Peto R; Critical Leg Ischaemia Prevention Study (CLIPS) Group. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med 2007; 261: 276-284 (Pubitemid 46255949)
36. Fox KA, Metha SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial. Circulation 2004; 110: 1202-1208 (Pubitemid 39202333)
37. Comerota AJ. Endovascular and surgical revascularization for patients with intermittent claudication. Am J Cardiol 2001; 87: 34D-43D.
38. Keller TT, Squizzato A, Middeldorp S. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database Syst Rev. 2007; (3): CD005158.
39. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717
40. Dalainas I, Nano G, Bianchi P, et al. Dual antiplatelet regime versus acetyl-acetic acid for carotid artery stenting. Cardiovasc Intervent Radiol 2006; 29: 519-521 (Pubitemid 43822992)
41. Verheugt WF, Montalescot G, Sabatine MS, et al. Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial. J Thromb Thrombolysis 2007; 23: 173-179 (Pubitemid 46564116)
42. Cuisset T, Frere C, Quilici J, et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006; 48: 1339-1345 (Pubitemid 44436814)
43. Plosker GL, Lyseng-Williamson KA. Clopidogrel: a review of its use in the prevention of thrombosis. Drugs 2007; 67: 613-646 (Pubitemid 46442637)